Myovant Sciences Ltd. (NYSE:MYOV) Major Shareholder Chemical Co. Ltd. Sumitomo Buys 30,000 Shares

Myovant Sciences Ltd. (NYSE:MYOV) major shareholder Chemical Co. Ltd. Sumitomo acquired 30,000 shares of the business’s stock in a transaction dated Friday, September 10th. The shares were acquired at an average cost of $25.11 per share, with a total value of $753,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Chemical Co. Ltd. Sumitomo also recently made the following trade(s):

  • On Monday, September 13th, Chemical Co. Ltd. Sumitomo acquired 83,178 shares of Myovant Sciences stock. The stock was purchased at an average cost of $23.38 per share, for a total transaction of $1,944,701.64.
  • On Tuesday, September 7th, Chemical Co. Ltd. Sumitomo bought 33,200 shares of Myovant Sciences stock. The stock was purchased at an average price of $26.23 per share, with a total value of $870,836.00.
  • On Friday, September 3rd, Chemical Co. Ltd. Sumitomo bought 31,200 shares of Myovant Sciences stock. The stock was purchased at an average price of $26.76 per share, with a total value of $834,912.00.
  • On Monday, August 30th, Chemical Co. Ltd. Sumitomo bought 70,000 shares of Myovant Sciences stock. The shares were acquired at an average cost of $23.92 per share, with a total value of $1,674,400.00.
  • On Friday, August 27th, Chemical Co. Ltd. Sumitomo bought 37,038 shares of Myovant Sciences stock. The stock was bought at an average price of $23.17 per share, for a total transaction of $858,170.46.
  • On Wednesday, August 25th, Chemical Co. Ltd. Sumitomo purchased 28,709 shares of Myovant Sciences stock. The shares were acquired at an average price of $22.44 per share, for a total transaction of $644,229.96.
  • On Monday, August 23rd, Chemical Co. Ltd. Sumitomo purchased 55,447 shares of Myovant Sciences stock. The shares were acquired at an average price of $22.30 per share, for a total transaction of $1,236,468.10.
  • On Friday, August 20th, Chemical Co. Ltd. Sumitomo purchased 46,478 shares of Myovant Sciences stock. The stock was bought at an average cost of $20.86 per share, for a total transaction of $969,531.08.
  • On Wednesday, August 18th, Chemical Co. Ltd. Sumitomo purchased 17,116 shares of Myovant Sciences stock. The shares were purchased at an average price of $21.45 per share, with a total value of $367,138.20.
  • On Monday, August 16th, Chemical Co. Ltd. Sumitomo purchased 48,167 shares of Myovant Sciences stock. The shares were purchased at an average price of $21.37 per share, with a total value of $1,029,328.79.

Shares of MYOV opened at $21.51 on Wednesday. The company has a 50-day simple moving average of $21.86 and a 200-day simple moving average of $21.68. The company has a market capitalization of $1.98 billion, a PE ratio of -6.87 and a beta of 2.87. Myovant Sciences Ltd. has a 52-week low of $13.42 and a 52-week high of $30.90.

Myovant Sciences (NYSE:MYOV) last issued its quarterly earnings data on Wednesday, July 28th. The company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.46). The company had revenue of $41.06 million for the quarter, compared to analysts’ expectations of $61.19 million. As a group, equities analysts forecast that Myovant Sciences Ltd. will post -2.24 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth about $296,000. Integral Health Asset Management LLC boosted its stake in shares of Myovant Sciences by 30.8% during the 2nd quarter. Integral Health Asset Management LLC now owns 85,000 shares of the company’s stock worth $1,935,000 after purchasing an additional 20,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth about $588,000. Marshall Wace North America L.P. acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth about $4,394,000. Finally, Morgan Stanley boosted its stake in shares of Myovant Sciences by 9.2% during the 2nd quarter. Morgan Stanley now owns 240,056 shares of the company’s stock worth $5,465,000 after purchasing an additional 20,212 shares during the last quarter. 33.78% of the stock is currently owned by hedge funds and other institutional investors.

MYOV has been the subject of several research analyst reports. JMP Securities restated a “buy” rating on shares of Myovant Sciences in a report on Wednesday, August 25th. Zacks Investment Research cut shares of Myovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, August 10th. SVB Leerink began coverage on shares of Myovant Sciences in a research note on Thursday, September 9th. They set a “market perform” rating and a $24.00 price target for the company. Finally, The Goldman Sachs Group began coverage on shares of Myovant Sciences in a research note on Friday, August 20th. They set a “neutral” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.57.

Myovant Sciences Company Profile

Myovant Sciences, Inc is a clinical-stage biopharmaceutical company. The firm focuses on the development and commercialization of therapies for the treatment of women’s health and endocrine diseases. It offers ORGOVYXTM (relugolix), a oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer.

Further Reading: What is the Nikkei 225 index?    

Insider Buying and Selling by Quarter for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.